Opportunistic Infections

Immune Modulator Strengthens Resistance to AIDS Infections

Published in AIDS Weekly, June 3rd, 1996

Dimethaid Research Inc., Markham, Ontario, Canada, announced that a Phase II clinical trial of WF10, an immune system modulator, has shown that WF10 effectively stimulates the immune system of AIDS patients to resist the opportunistic infections associated with the disease.

The trial, directed by Dr. Stephen R. Raffanti of Vanderbilt University Hospital, Nashville, Tennessee, was a double blind, three month, randomized placebo-controlled study involving adult patients with late stage AIDS (mean CD4 count equals 30).

Data filed with the U.S. Food and Drug Administration (FDA) indicated a significant statistical difference between the groups in four...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1996-06-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry